Literature DB >> 15592718

High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity.

Teresa Rodriguez1, Rosa Méndez, Chrissy H Roberts, Francisco Ruiz-Cabello, I Anthony Dodi, Miguel Angel López Nevot, Laura Paco, Isabel Maleno, Steven G E Marsh, Graham Pawelec, Federico Garrido.   

Abstract

Malignant transformation of cells is frequently associated with abnormalities in human leukocyte antigen (HLA) expression. MHC class I loss or down-regulation in cancer cells is a major immune escape route used by a large variety of human tumours to evade antitumour immune responses mediated by cytotoxic T lymphocytes. The goal of our study was to explore HLA genotyping and phenotyping in a variety of melanoma tumour cell lines. A total of 91 melanoma cell lines were characterised for HLA class I and II genotype. In addition, 61 out of the 91 cell lines were also analysed for HLA class I and II cell surface molecule expression by flow cytometry. Unexpectedly, we found that 19.7% of the melanoma cell lines were homozygous for HLA class I genotypes, sometimes associated with HLA class II homozygosity (8.79%) and sometimes not (10.98%). The frequency of homozygosity was significantly higher compared with the control groups (1.6%). To identify the reasons underlying the high frequency of HLA homozygosity we searched for genomic deletions using eight pairs of highly polymorphic microsatellite markers covering the entire extended HLA complex on the short arm of chromosome 6. Our results were compatible with hemizygous deletions and suggest that loss of heterozygosity on chromosome arm 6p is a common feature in melanoma cell lines. In fact, although autologous normal DNA from the patients was not available and could not be tested, the retention in some cases of heterozygosity for a number of microsatellite markers would indicate a hemizygous deletion. In the rest of the cases, markers at 6p and 6q showed a single allele pattern indicating the probable loss of part or the whole of chromosome 6. These results led us to conclude that loss of heterozygosity in chromosome 6 is nonrandom and is possibly an immunologically relevant event in human malignant melanoma. Other well-established altered HLA class I phenotypes were also detected by flow cytometry that correspond to HLA class I total loss and HLA-ABC and/or specific HLA-B locus down-regulation.

Entities:  

Mesh:

Year:  2004        PMID: 15592718     DOI: 10.1007/s00262-004-0561-5

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  4 in total

1.  Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele.

Authors:  Yuefang Wang; Aurora O'Brate; Wei Zhou; Paraskevi Giannakakou
Journal:  Cell Cycle       Date:  2005-12-18       Impact factor: 4.534

2.  The evolving understanding of immunoediting and the clinical impact of immune escape.

Authors:  Caroline E McCoach; Trever G Bivona
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

3.  Distinct MHC gene expression patterns during progression of melanoma.

Authors:  Yan Degenhardt; Jia Huang; Joel Greshock; Galene Horiates; Katherine Nathanson; Xiaolu Yang; Meenhard Herlyn; Barbara Weber
Journal:  Genes Chromosomes Cancer       Date:  2010-02       Impact factor: 5.006

Review 4.  Testing the theory of immune selection in cancers that break the rules of transplantation.

Authors:  Ariberto Fassati; N Avrion Mitchison
Journal:  Cancer Immunol Immunother       Date:  2009-12-22       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.